{
    "pmcid": "7755911",
    "qa_pairs": {
        "What is one potential application of NIH-CoVnb-112 besides therapeutic use?": [
            "Diagnostic tool",
            "Vaccine adjuvant",
            "Gene therapy vector",
            "Antiviral drug"
        ],
        "What is the EC50 value of the lead nanobody candidate NIH-CoVnb-112 in blocking the RBD-ACE2 interaction?": [
            "0.3 \u00b5g/mL",
            "4.9 nM",
            "40 mg/L",
            "10^8 clones"
        ],
        "What is the primary target of the nanobodies developed in the study for therapeutic application against COVID-19?": [
            "SARS-CoV-2 spike receptor binding domain (RBD)",
            "Human angiotensin converting enzyme 2 (ACE2)",
            "SARS-CoV-1 spike protein RBD",
            "SARS-CoV-2 nucleocapsid protein"
        ],
        "Which expression system was used to produce NIH-CoVnb-112 to mitigate endotoxin risks?": [
            "Pichia pastoris",
            "Escherichia coli",
            "Mammalian cell culture",
            "Baculovirus-infected insect cells"
        ],
        "Which method was used to isolate nanobodies that block the interaction between the SARS-CoV-2 spike RBD and ACE2?": [
            "Immobilizing ACE2 and using biotinylated RBD",
            "Using a yeast display library",
            "Employing a CRISPR-Cas9 screening approach",
            "Utilizing a mammalian cell surface display system"
        ]
    }
}